BS_D0RDN4K5
Embryonal tumors
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Embryonal tumors
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Embryonal tumors
- overall_survival_months
- 52.496714848883045
- age_years
- 16.663
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.491
- G2M_CHECKPOINT+0.261
- E2F_TARGETS+0.226
- DNA_REPAIR+0.172
- MYC_TARGETS_V1+0.157
- UNFOLDED_PROTEIN_RESPONSE+0.112
- MITOTIC_SPINDLE+0.086
- SPERMATOGENESIS-0.018
- KRAS_SIGNALING_DN-0.020
- PEROXISOME-0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.582
- TNFA_SIGNALING_VIA_NFKB-0.575
- IL6_JAK_STAT3_SIGNALING-0.558
- INFLAMMATORY_RESPONSE-0.519
- ALLOGRAFT_REJECTION-0.511
- COMPLEMENT-0.502
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.498
- COAGULATION-0.493
- TGF_BETA_SIGNALING-0.486
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1BWP5MCT | medulloblastoma | — | 0.978 |
| 2 | BS_V9HVBBDW | medulloblastoma | — | 0.954 |
| 3 | BS_3NWQXPQV | medulloblastoma | — | 0.953 |
| 4 | BS_GE2RVZE6 | medulloblastoma | — | 0.952 |
| 5 | BS_9PB3XH5D | medulloblastoma | — | 0.952 |
| 6 | BS_YEB88D32 | medulloblastoma | — | 0.948 |
| 7 | BS_A87NPZAP | medulloblastoma | — | 0.946 |
| 8 | BS_9V633J1X | medulloblastoma | — | 0.945 |
| 9 | BS_DBEX7AG2 | Embryonal tumors | — | 0.944 |
| 10 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.491 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.261 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.226 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.172 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.157 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.112 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.086 | Inavolisib | — uncovered |